Kenneth Galbraith

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Surrey, British Columbia, Canada
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Daniel Dex, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Kenneth Galbraith

Form 4 holding Chair & CEO, Director

Zymeworks Inc.

Security class
Common Stock
Shares / value
226,842
Estimated value
$5,143,302
Report date
12 Jan 2026
Price
$22.67
Ownership
Direct
Form 4 holding Chair & CEO, Director

Zymeworks Inc.

Security class
Restricted Stock Unit
Shares / value
144,000
Estimated value
$2,865,427
Report date
12 Jan 2026
Price
$14.92
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

MACROGENICS INC

Security class
Stock Option (right to buy)
Shares / value
15,000
Estimated value
$22,650
Report date
13 May 2021
Price
$1.51
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chair, President & CEO, Director

Zymeworks Inc.

Security class
Stock Option (Right to Buy)
Shares / value
500,000
Estimated value
Report date
15 Jan 2022
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Chair & CEO, Director

Zymeworks Inc.

Security class
Performance Stock Unit
Shares / value
222,000
Estimated value
Report date
12 Jan 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chair & CEO, Director

Zymeworks Inc.

Security class
Stock Option (Right to Buy)
Shares / value
216,000
Estimated value
Report date
12 Jan 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Kenneth Galbraith

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .